Natco Pharma Raises Adcock Ingram Stake to 49% in South Africa Push

The Indian drugmaker expands its Southern African footprint with a new investment, aiming to accelerate growth in the emerging pharmaceutical market.

HYDERABAD — Natco Pharma Limited announced on Wednesday that its board has approved a significant increase in its stake in Adcock Ingram Holdings Limited, raising its ownership from 35.75% to 49%. The move marks a deepened commitment by the Indian pharmaceutical firm to the South African market, serving as a cornerstone of its international expansion strategy.

According to a regulatory filing submitted to the Bombay Stock Exchange (BSE), Natco Pharma will acquire 19,618,825 shares at a price of ZAR 92.50 per share. The transaction, valued at approximately ₹1,069 crore, represents a key phase in the company’s ongoing efforts to consolidate its position within the Southern African pharmaceutical sector.

Expanding Regional Capabilities

In addition to the equity increase, Natco Pharma has sanctioned an investment of up to ₹1,400 crore into its wholly-owned subsidiary, Natco Pharma South Africa Proprietary Limited. This capital injection is designed to bolster regional operations and facilitate the broader distribution of Natco’s specialized product portfolio, which includes complex generics and oncology treatments.

The company’s strategic interest in Adcock Ingram remains focused on leveraging the South African firm’s extensive distribution network and long-standing presence in the prescription, over-the-counter (OTC), and hospital product segments. Adcock Ingram, a prominent player in the region, reported a topline revenue of US$ 423 million with an EBITDA of approximately US$ 59 million for the nine-month period ending March 31, 2026.

A Gateway to African Growth

For Natco Pharma, South Africa serves as a critical gateway to the wider African continent. The decision to increase its stake to 49% highlights the company's confidence in the regulatory and economic framework of the region. As Natco Pharma continues to pivot toward high-growth emerging markets, the integration of 49% of Adcock Ingram’s profit after tax into its financial books is expected to strengthen its consolidated earnings profile.

“The board’s decision underscores our long-term vision for the African market,” an industry analyst noted, citing the synergies between Natco’s research-focused manufacturing and Adcock Ingram’s market access.

Strategic Implications

This investment follows a period of rapid consolidation for the two firms. Following previous strategic transactions in 2025, Adcock Ingram has continued to operate as a private entity, with Natco serving as a primary strategic shareholder alongside the Bidvest Group. The current expansion is poised to streamline supply chains and enable more efficient deployment of capital for product development and market penetration.

Official Sources

The details regarding this investment were confirmed through a corporate filing made to the National Stock Exchange of India (NSE) on July 8, 2026. Official statements were provided by the company secretary and compliance officer, Venkat Ramesh Chekuri.

Why It Matters

For investors, the increase to 49% ownership signals that Natco Pharma is moving closer to an equal partnership in the region. The move provides a clearer path for Natco to utilize Adcock Ingram’s manufacturing and distribution infrastructure, potentially lowering costs for the introduction of new therapies in Southern Africa. For the healthcare sector, the partnership aims to provide wider access to affordable medications across multiple therapeutic areas.

Key Facts at a Glance

• Stake Increase: Natco Pharma’s ownership in Adcock Ingram rises from 35.75% to 49%.

• Transaction Value: The acquisition of 19.6 million shares is valued at approximately ₹1,069 crore.

• Subsidiary Investment: An additional ₹1,400 crore investment in Natco Pharma South Africa Proprietary Limited.

• Market Focus: Strengthening footprint in the Southern African prescription, OTC, and hospital segments.

FAQ Section

What is the new ownership percentage of Natco Pharma in Adcock Ingram?

Following the latest board approval, Natco Pharma’s stake will increase to 49%.

What is the purpose of the ₹1,400 crore investment?

The funds are earmarked for Natco Pharma South Africa Proprietary Limited to support operational expansion and regional market growth.

How does this acquisition impact the company’s financial reporting?

Post-transaction, Natco Pharma will consolidate 49% of the profit after tax of Adcock Ingram into its own financial records.

Why is the South African market significant for Natco Pharma?

South Africa acts as a strategic gateway for the company’s expansion into the broader African pharmaceutical market, allowing for increased product distribution and brand presence.

Source: Natco Pharma Limited, National Stock Exchange of India (NSE), Bombay Stock Exchange (BSE)